Sabio Q1 FY26 net loss widens to US$4.42 million; revenue falls to US$7.16 million
ALPS Medical Breakthroughs ETF
ALPS Medical Breakthroughs ETF SBIO | 0.00 |
- Sabio posted Q1 2026 revenue of US$7.16 million, down 21.23% year over year; net loss widened to US$4.42 million.
- Gross margin fell 8 percentage points to 53%, reflecting aggressive January pricing and a shift of higher-margin political and advocacy spend to H2.
- Adjusted EBITDA loss widened to US$3.43 million; gross revenue totaled US$8.2 million, down from the prior-year quarter.
- International revenue rose about 1,173% year over year, while programmatic CTV/OTT revenue increased about 1,174%; together they made up about 62% of gross revenue.
- More than US$5 million in political and advocacy commitments were secured for 2026; management said gross revenue is tracking more than 35% higher sequentially.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sabio Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605251750PR_NEWS_USPR_____LA67259) on May 25, 2026, and is solely responsible for the information contained therein.
